Volume : 13, Issue : 03, March – 2026

Title:

CLINICAL CHARACTERISTICS AND RISK FACTORS FOR SEVERE COVID-19 IN PATIENTS WITH TYPE 2 DIABETES

Authors :

Ramy Abdallah, Saja Albrnawi

Abstract :

This study aimed to evaluate the clinical characteristics and identify risk factors associated with severe COVID-19 in patients with Type 2 Diabetes Mellitus (T2DM). A total of 74 diabetic patients diagnosed with COVID-19 were included. Among them, 27 patients (36.5%) developed severe disease, and 10 patients (13.5%) died.
Compared with non-severe cases, patients with severe COVID-19 had significantly higher levels of blood glucose, serum amyloid A (SAA), C-reactive protein (CRP), and interleukin-6 (IL-6). In contrast, severe cases demonstrated lower levels of albumin, total cholesterol, high-density lipoprotein (HDL), small dense low-density lipoprotein (sdLDL), and CD4+ T lymphocyte counts.
Logistic regression analysis identified reduced CD4+ T lymphocyte counts (OR = 0.988, 95% CI: 0.979–0.997) and elevated SAA levels (OR = 1.029, 95% CI: 1.002–1.058) as independent risk factors for severe COVID-19 in patients with T2DM.
These findings suggest that immune dysfunction and inflammatory response play a critical role in disease severity among diabetic patients with COVID-19, highlighting the importance of early monitoring and risk stratification in this high-risk population.
Keywords: COVID-19, Type 2 Diabetes Mellitus, Disease Severity, Risk Factors, Hyperglycemia, Dyslipidemia, CD4+ T Lymphocytes

Cite This Article:

Please cite this article in press Ramy Abdallah et al., Clinical Characteristics And Risk Factors For Severe Covid-19 In Patients With Type 2 Diabetes., Indo Am. J. P. Sci, 2026; 13(03).

REFERENCES:

1. World Health Organization. Naming the coronavirus disease (COVID-19) https://www.who.int/emergencies/diseases/novelcoronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid2019)-and-the-virus-that-causes-it 2020-02-11. 283
2. World Health Organization. Coronavirus disease 2019 (COVID-19) situation https://www.who.int/docs/default-source/coronaviruse/situation-reports/ 285 20200421-sitrep-92-covid-19.pdf?sfvrsn=38e6b06d_6. 286
3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel co287 ronavirus in Wuhan, China. Lancet 2020;395:497-506. 288
4. Deng SQ, Peng HJ. Characteristics of and public health responses to the coronavirus 289 disease 2019 outbreak in China. J Clin Med 2020;9. 290
5. Wu H, Lau ESH, Ma RCW, et al. Secular trends in all-cause and cause-specific mortal291 ity rates in people with diabetes in Hong Kong, 2001-2016: a retrospective cohort 292 study. Diabetologia 2020;63:757-66. 293
6. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus 294 disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases 295Q6 from the Chinese Center for Disease Control and Prevention. JAMA 2020.
7. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpa- 296 tients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 297 2020;395:1054-62. 298
8. Interim guidance for novel coronavirus pneumonia (trial implementation of revised 299 fifth edition). National Health and Health Commission. 2020, http://www.nhc.gov. 300 cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml. 301.
9. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases 302 of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 303 2020;395:507-13. 304
10. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients 305 with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 306 2020. 307 Q7
11. Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in 308 patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020. 309 Q8.
12. Wypych TP, Marsland BJ, Ubags NDJ. The impact of diet on immunity and respiratory 310 diseases. Ann Am Thorac Soc 2017;14:S339-47. 311
13. Valdes-Ramos R, Martinez-Carrillo BE, Aranda II G, et al. Diet, exercise and gut muco- 312 sal immunity. Proc Nutr Soc 2010;69:644-50. 313
14. Cabrera-Perez J, Condotta SA, Badovinac VP, Griffith TS. Impact of sepsis on CD4 T cell 314 immunity. J Leukoc Biol 2014;96:767-77. 315
15. Gleeson LE, Sheedy FJ. Metabolic reprogramming & inflammation: fuelling the host 316 response to pathogens. Semin Immunol 2016;28:450-68. 317.
16. Zhang J, Wang X, Jia X, et al. Risk factors for disease severity, unimprovement, and 318 mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect 2020. 319 Q9.
17. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with 320 SARS-CoV-2 in Wuhan, China. Allergy 2020. 321 Q10
18. Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020. Q11.
19. Schiffrin EL, Flack JM, Ito S, et al. Hypertension and COVID-19. Am J Hypertens 2020. Q1.